Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Executive Vice President | August 12, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 253,390 |
Reported balance
After 2026-08-12 transaction · row 1
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 146,403 · Balance 253,390 F1: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2021 Filed Mar 2, 2021 21:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 35,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016058 · doc4.xml · derivative · entry 5 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,860 Underlying: Class A Common Stock · 35,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock units represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On February 27, 2020, the reporting person was granted 142,480 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2020, the reporting person was granted 142,480 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 11,548 | $5.39 | $62,243.72 |
DisclosureSEC source: 0001209191-21-016058 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,799 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 35,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-016058 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock units represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:12 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 4,442 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012453 · doc4.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,883 Underlying: Class A Common Stock · 4,442 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:12 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 1,326 | $3.55 | $4,707.30 |
DisclosureSEC source: 0000899243-20-012453 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,727 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:12 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 4,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012453 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 11,728 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006809 · doc4.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,186 Underlying: Class A Common Stock · 11,728 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 46,914 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 46,914 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 4,228 | $3.85 | $16,277.80 |
DisclosureSEC source: 0000899243-20-006809 · doc4.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,611 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 11,728 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-006809 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 01:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 284,960 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006636 · doc4.xml · derivative · entry 2 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,960 Underlying: Class A Common Stock · 284,960 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units. F5 · derivative.exercise_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. F5 · derivative.expiration_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 01:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 142,480 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006636 · doc4.xml · derivative · entry 1 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,480 Underlying: Class A Common Stock · 142,480 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on February 27, 2021. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on February 27, 2021. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 95,525 | Not disclosed Strike: $2.75 | Not disclosed |
DisclosureSEC source: 0001723128-19-000130 · wf-form4_157377041302891.xml · derivative · entry 4 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,525 Underlying: Class A Common Stock · 95,525 shares Expires 2029-03-01 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Disposition to issuerStock Option · Derivative | 95,525 | Not disclosed Strike: $13.50 | Not disclosed |
DisclosureSEC source: 0001723128-19-000130 · wf-form4_157377041302891.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 95,525 shares Expires 2029-03-01 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 72,661 | Not disclosed Strike: $2.75 | Not disclosed |
DisclosureSEC source: 0001723128-19-000130 · wf-form4_157377041302891.xml · derivative · entry 2 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,661 Underlying: Class A Common Stock · 72,661 shares Expires 2028-05-07 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Disposition to issuerStock Option · Derivative | 72,661 | Not disclosed Strike: $15.01 | Not disclosed |
DisclosureSEC source: 0001723128-19-000130 · wf-form4_157377041302891.xml · derivative · entry 1 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 72,661 shares Expires 2028-05-07 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:42 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 4,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000087 · wf-form4_155743816112512.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,325 Underlying: Class A Common Stock · 4,441 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:42 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 1,366 | $13.44 | $18,359.04 |
DisclosureSEC source: 0001723128-19-000087 · wf-form4_155743816112512.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,111 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:42 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 4,441 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-19-000087 · wf-form4_155743816112512.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:02 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 46,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000035 · wf-form4_155182696507642.xml · derivative · entry 2 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,914 Underlying: Class A Common Stock · 46,914 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2020. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:02 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 95,525 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001723128-19-000035 · wf-form4_155182696507642.xml · derivative · entry 1 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,525 Underlying: Class A Common Stock · 95,525 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2020. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:51 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 50,000 | $23.46 | $1,173,000.00 |
DisclosureSEC source: 0000899243-18-023154 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,036 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $23.53. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 21:14 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass A Common Stock | 216,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019666 · doc4.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,036 F1 · kind: Represents a pro rata in-kind distribution of Class A Common Stock by APHC Holdings, LLC to its members who are holders of profit participation units. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 17,766 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012154 · doc4.xml · derivative · entry 2 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,766 Underlying: Class A Common Stock · 17,766 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 72,661 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-012154 · doc4.xml · derivative · entry 1 Shah Nikita · CIK 0001738061 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,661 Underlying: Class A Common Stock · 72,661 shares Expires 2028-05-07 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.